SAFETY DATA SHEET

Zoetis New Zealand Limited



Section 1: Identification of the Substance and Supplier

Trade Name: LINCO-SPECTIN® Soluble Powder

ACVM Registration No.: A002098

Classification: Restricted Veterinary Medicine (RVM)

Recommended Use: Injectable antibiotic for use in poultry as an aid in treatment and

> prevention of chronic respiratory disease associated with mycoplasma and coliform infections, and in swine for treatment of swine dysentery, bacterial enteritis caused by E. coli or Salmonella, infectious arthritis alone or complicated by septicaemia, arthritis caused by streptococci,

staphylococci and mycoplasma organisms.

Company Details: Zoetis New Zealand Limited

Level 4, 8 Mahuhu Crescent Address:

> **Auckland Central** Auckland 1010 New Zealand

Telephone No.: 0800 963 847 (Business Hours)

Emergency Telephone

No.:

0800 POISON (0800 764 766) National Poisons Centre: In an emergency dial 111

Emergency Services:

Date of Preparation: 1 July 2019

Section 2: Hazards Identification

Hazard Classification: 6.1E, 6.4A

Priority Identifier(s): WARNING - KEEP OUT OF REACH OF CHILDREN

Secondary Identifier(s): May be harmful if swallowed, inhaled or absorbed through the skin. 6.1E

May cause eye irritation. Avoid contact with the eyes. 6.4A

Section 3: Composition / Information on Ingredients		
Chemical Identity of Ingredients		
Ingredient	CAS No.	Concentration
Lincomycin (as Lincomycin hydrochloride)	859-18-7	220 g/kg
Spectinomycin (as Spectinomycin sulphate tetrahydrate)	64058-48-6	445 g/kg
Other ingredients determined not to be hazardous.	-	-

This is a commercial product whose exact ratio of components may vary. Trace quantities of impurities are also likely.

Zoetis New Zealand Limited LINCO-SPECTIN® Soluble Powder

Page 1 of 7 Issued: 1 July 2019

Section 4: First Aid Measures

Necessary First Aid Measures:

For advice contact the National Poisons Centre at 0800 POISON (0800 764 766) or a doctor immediately. If the patient is not breathing begin artificial respiration and seek medical advice immediately. Never give fluids or induce vomiting if a patient is unconscious or convulsing, regardless of injury.

Self-Injection: Immediate medical advice should be sought on the

management of all instances of accidental self-injection, particularly those near a joint or associated with bruising. Allow the wound to bleed freely and avoid squeezing the injection site to avoid spread of the product. Clean the wound thoroughly with soap and water, then keep it clean and dry.

Ingestion: DO NOT induce vomiting. If the patient is conscious wash

mouth out with water. Do not give anything by mouth to an

unconscious person. Seek medical advice immediately.

Eye Contact: Flush the eye(s) out with running water for at least 15

> minutes. Removal of contact lenses should be done with caution within 5 minutes of exposure. If symptoms develop

seek medical advice immediately.

Skin Contact: Remove any contaminated clothing and wash the affected

area immediately with soap and water. If symptoms develop

seek medical advice immediately.

Inhalation: Move the patient to fresh air. If symptoms develop seek

medical advice immediately.

Overexposure may cause skin, eye and upper respiratory tract irritation or **Poisoning Symptoms:**

> allergic reactions. Repeated over exposure to lincomycin hydrochloride may cause abdominal cramps, diarrhoea and colitis. This may begin several weeks after exposure has ceased. Hypersensitivity to lincomycin or clindamycin may

be aggravated by exposure.

Workplace Facilities: No specific facilities required. Standard emergency equipment must be

available.

Hygiene Practices: Avoid self-injection, ingestion, contact with skin and eyes, and inhalation of

> dusts, mists or vapours. Do not eat, drink or smoke while using this product. Wash hands and exposed skin before eating, drinking or smoking and after

work. Wash any protective clothing after use.

Notes for Medical Personnel:

Accidental self-injection may lead to an inflammatory response and deep injections, particularly those near a joint or associated with bruising should be treated medically or surgically. Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Treatment of exposure should be directed at the control of symptoms and the clinical condition of the patient. Note the

nature of this product.

Section 5: Fire-Fighting Measures

Type of hazard: This product is not flammable, however, irritating and possibly toxic gases

may be generated by thermal decomposition or combustion.

Fire Hazard Properties: Hazardous combustion products include carbon monoxide, carbon dioxide,

oxides of nitrogen and sulphur, hydrochloric acid, hydrogen chloride and

other chlorine and sulphur containing compounds.

Regulatory Requirements: Not applicable.

Extinguishing Media &

Methods:

Use dry chemical, foam, carbon dioxide or water to extinguish fires

involving this product.

Hazchem Code: Not allocated.

Recommended Protective

Clothing:

During large-scale fire fighting operations wear approved positive pressure, self-contained breathing apparatus and full protective turn-out gear.

Evacuate area and fight fire from a safe distance.

Section 6: Accidental Release Measures

Personal Precautions: Personnel involved in clean-up should wear appropriate personal

protective equipment to minimise exposure. This may include eye

protection, chemically resistant gloves, boots and overalls.

Environmental Precautions:

Prevent material from entering surface water drains or waterways. If a significant quantity of material enters drains, advise emergency services.

Procedure for Spills: 1. Non-essential personnel should be evacuated from the affected area.

2. Stop leak and contain the source of spill if it is safe to do so. Reposition any leaking containers to minimise further leakage.

3. Absorb the spill with an absorbent material (e.g. sand).

4. Collect the spilled material into labelled containers for disposal, minimising dust generation.

5. Decontaminate the spill area thoroughly with detergent and water, preventing runoff from entering drains.

Procedure for Disposal: Contaminated material

Contaminated material must be disposed of at an approved landfill or other approved facility in accordance with local, regional and national requirements. Avoid contamination of any water supply with product or empty container.

Section 7: Handling and Storage

Handling

Precautions for Safe

Handling:

No special technical protective measures required. No special handling

advice required.

Regulatory Requirements: Not re

Not required.

Handling Practices: Avoid self-injection, ingestion, contact with skin and eyes, and inhalation

of dusts, mists or vapours. Do not eat, drink or smoke while handling this product. Wash hands and exposed skin before eating, drinking or

smoking and after work. Wash any protective clothing after use.

Approved Handlers: Approved handlers are not required for this product.

Zoetis New Zealand Limited LINCO-SPECTIN® Soluble Powder

Page 3 of 7 Issued: 1 July 2019

Storage

Conditions for Safe

Storage:

Store below 30°C (Room Temperature). Keep out of reach of children. Store in a well ventilated area in the original container, tightly closed,

away from foodstuffs.

Store Site Requirements: No additional requirements.

Packaging: Store in the original container, away from foodstuffs.

Section 8: Exposure Control / Personal Protection

Always Read and Follow the Label Instructions and Warnings

Workplace Exposure Guidelines

Workplace Exposure

Standards:

A time weighted average (TWA) concentration for an 8-hour day and a 5-day week has not been established by NOHSC Australia for any of the major ingredients in this product. There is a blanket limit of 10 mg/m³ for dusts or mists when limits have not otherwise been established.

Application in the Workplace:

The nature of this product makes it unlikely that this level will be approached during normal handling.

Exposure Standards
Outside the Workplace:

None set.

Engineering Controls: Engineering controls should be used as the primary means to control

exposures. Use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended

exposure limits.

Personal Protection: The following instructions are for those coming into frequent and / or lengthy

contact with this product. For occasional handling employ precautions suitable for the conditions under which the product is being handled.

Hands: Impervious gloves are recommended if skin contact is

possible and for bulk processing operations.

Eyes: It is always prudent to utilise protective eyewear.

Skin: When prolonged or frequently repeated contact could occur,

utilise chemically protective clothing. Selection of specific items such as a face shield, gloves, boots, or overalls will

depend on the situation.

Respiratory: Respiratory protection is not normally required; however, if

necessary utilise an air-purifying respirator that complies

with NZ standards.

General Hygiene: Change work clothes regularly. Avoid self-injection, ingestion, contact with

skin and eyes, and inhalation of dusts, mists or vapours. Do not eat, drink or smoke while handling this product. Wash hands and exposed skin before eating, drinking or smoking and after work. Wash any protective clothing

after use.

Section 9: Physical and Chemical Properties

Appearance: White powder

Odour: Slight

Density: No data available

Melting Point: 148°C

Boiling Point: Not applicable pH: No data available

Solubility in Water: Very soluble (500 -1,000 mg/mL)

Flashpoint: Not applicable. This product is not flammable

Oxidising Properties: Not applicable. This product is not an oxidiser

Corrosive Properties: Not applicable. This product is not corrosive

Vapour Pressure: Not applicable

Section 10: Stability and Reactivity

Stability of the Substance: This product is stable under normal conditions of use.

Conditions to Avoid: Store as recommended. No special conditions to avoid.

Material to Avoid: As a precautionary measure, keep away from strong oxidisers.

Hazardous Decomposition

Products:

This product is unlikely to spontaneously decompose. Hazardous combustion products include carbon monoxide, carbon dioxide, oxides of nitrogen and sulphur, hydrochloric acid, hydrogen chloride and other

chlorine and sulphur containing compounds.

Hazardous Polymerisation: This product is unlikely to spontaneously polymerise.

Specific Data: No specific data available.

Section 11: Toxicological Information

HSNO Classifications

6.1E May be harmful if swallowed, inhaled or absorbed through the skin.

6.4A May cause eye irritation. Avoid contact with the eyes.

Acute Effects

Acute Toxicity: Lincomycin hydrochloride:

• Intravenous LD₅₀ (Rat): 342 mg/kg

• Intravenous LD₅₀ (Mouse): 214 mg/kg

• Oral LD₅₀ (Rat): >4,000 mg/kg

Intraperitoneal (Mouse): 1,000 mg/kg

Subcutaneous LD₅₀ (Rat): 9,778 mg/kg

Spectinomycin sulphate tetrahydrate:

• Intravenous LD₅₀ (Mouse): 1,022 mg/kg

Oral LD₅₀ (Rat): >5,000/kg/kg

Intraperitoneal LD₅₀ (Mouse): 3,577 mg/kg

Zoetis New Zealand Limited LINCO-SPECTIN® Soluble Powder

Page 5 of 7 Issued: 1 July 2019 Sensitisation: May cause hypersensitivity reactions. Hypersensitivity reactions such as

angioneurotic oedema, serum sickness and anaphylaxis have been reported from exposure to lincomycin hydrochloride. Some of these people were known to be sensitive to penicillin. Rare instances of erythema multiforme, some resembling Stevens-Johnson syndrome, have been associated with lincomycin hydrochloride.

Skin Contact: Spectinomycin sulphate tetrahydrate:

Non irritant (rabbit)

Eye Contact: Lincomycin hydrochloride:

Mild irritant (rabbit)

Spectinomycin sulphate tetrahydrate:

Mild irritant (rabbit)

Chronic / Long Term Effects

Repeated exposure to lincomycin hydrochloride may cause abdominal cramps, diarrhoea and colitis. This may begin several weeks after exposure has ceased.

Carcinogenicity: Ingredient is not listed as carcinogenic by IARC, NTP, or OSHA

Genotoxicity: Negative

Teratogenicity: No teratogenic effects seen in rats or dogs

Section 12: Ecotoxicity Information

HSNO Classifications

Not applicable. This product is not classified as ecotoxic.

The environmental characteristics of this material have not been fully evaluated. Avoid contamination of any water supply with product or empty container.

Ecotoxicity Effects

Toxicity to Birds:

Acute Toxicity to Fish:

Not applicable

Toxicity to Soil Dwelling Organisms:

Not applicable

Acute Toxicity to Bees:

Not applicable

Environmental Fate

Mobility: Lincomycin hydrochloride melts with decomposition at 148°C. It has no

measurable vapour pressure; therefore, it is not expected to enter the air. Lincomycin hydrochloride is very soluble in water (500 -1,000 mg/mL) and undergoes hydrolysis at both acid and base pHs at elevated temperatures. Lincomycin can be sorbed to soil, but is readily leached away from soils, lincomycin is expected to be relatively mobile and migrate toward the aquatic

compartment.

Persistence / Biodegradability:

Lincomycin hydrochloride can undergo hydrolysis at both acid and base pHs at elevated temperatures; however, in the pH range 3-6 at room temperature, degradation is small. Lincomycin bioactivity is readily degraded by mixtures of

urine, faeces and soil. The half-life of degradation was about 20 days.

Bioaccumulative Potential:

Lincomycin has a low octanol-water partition coefficient at all pHs. The octanol-water partition at pH 7 is 2.550. Calculated flowing and static bioaccumulation factors are 2.21 and 9.96, respectively. Lincomycin will be expected to migrate to the aquatic environment, but it should not bioaccumulate in aquatic organisms.

Abiotic Potential:

Lincomycin will have some initial inhibitory effects on the most sensitive microorganisms until it is degraded. Small amounts sent to sanitary sewage will not adversely affect the abiotic flora of sewage treatment facilities.

Section 13: Disposal Considerations

Product Disposal: Preferably dispose of product by use in accordance with label directions.

Otherwise dispose of product at an approved landfill, or other approved facility in accordance with local, regional and national regulations. Avoid contamination of

any water supply with product.

Container Disposal: Dispose of empty containers by wrapping in paper and putting in garbage for

disposal at an approved landfill, or other approved facility in accordance with local, regional and national regulations. Avoid contamination of any water supply with empty container. Used needles and syringes should immediately be placed

in a designated and appropriately labelled "sharps" container.

Section 14: Transport Information

Dangerous Goods Classification

UN No.:

Not applicable. This product is not a dangerous good.

Class:

Not applicable. This product is not a dangerous good.

Packing Group:

Not applicable. This product is not a dangerous good.

Proper Shipping Name:

Not applicable. This product is not a dangerous good.

Section 15: Regulatory Information

HSNO Approval No.: HSR002414

HSNO Controls: See <u>www.epa.govt.nz</u> for controls

ACVM Registration No.: A002098

ACVM Controls: See www.foodsafety.govt.nz for registration conditions

Section 16: Other Information

Note: This product is a veterinary medicine and must therefore be used in accordance with the container label directions. A comprehensive package of toxicological and environmental data for the active ingredients of this product has been submitted to the Government health and environment authorities and has been evaluated by expert toxicologists and environmental scientists.

CONTACT POINT: Zoetis New Zealand Limited: 0800 963 847 (Business Hours)

National Poisons Centre: 0800 POISON (0800 764 766)

Emergency Services: Dial 111

This Safety Data Sheet summarises our best knowledge of the health and safety hazard information of the product and how to safely handle and use the product in the workplace. Each user should read this SDS and consider the information in the context of how the product will be handled and used in the workplace including in conjunction with other products.

PLEASE READ ALL LABELS CAREFULLY BEFORE USING PRODUCT.

If clarification of further information is needed to ensure that an appropriate risk assessment can be made, the user should contact this company.

® Registered trademark© 2019 All rights reserved